Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
Strome
S E
SE
Department of Otolaryngology, University of Michigan, Ann Arbor 48109.
Krauss
J C
JC
Chang
A E
AE
Shu
S
S
D000818:Animals; D002986:Clinical Trials as Topic; D005544:Forecasting; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation; D008198:Lymph Nodes / Q000473:pathology; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation; D008546:Melanoma, Experimental / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D016853:Muromonab-CD3 / Q000494:pharmacology; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000628:therapy*; D012513:Sarcoma, Experimental / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000637:transplantation*
D007376:Interleukin-2; D016853:Muromonab-CD3